Compare S&P Global Inc (SPGI) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? S&P Global Inc trades at $407.54 (market cap $118.72B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.75 (market cap $58.74B). The key difference: S&P Global Inc is far larger — about 2× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| SPGI | TAK | |
|---|---|---|
Market Cap | $118.72B | $58.74B |
Volume | 1,647,917 | 3,110,994 |
Sector | Financials | Health |
52-Week High | $517.92 | $19.05 |
52-Week Low | $370.42 | $13.23 |
Typical Hold Time | 123 Days | 1 Days |
Enterprise Value | $130.21B | $86.65B |
Dividend Yield | 0.96% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $406.06, up 2.75% today, with strong analyst support (85.7% buy ratings) and a consensus price target of $509.50. The stock shows robust fundamentals, including 30.54% net income margin and consistent revenue growth, though technical indicators signal near-term bearish pressure. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives, positioning the company for future revenue streams.
Outlook remains positive due to high profitability, strategic acquisitions, and dominant market position, but risks include competitive pressures and macroeconomic sensitivity. The stock offers upside based on analyst targets, supported by stable cash flows and dividend payments, making it a compelling hold for long-term investors despite technical headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
